TerminatedNot Applicable

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Stopped: Study is replaced by some Risk Manag. Activities covering the whole Russian Federation. Primary objectives could not be met due to critical missing information.

Russia199 participantsStarted 2011-08

Plain-language summary

This is an observational trial in Rheumatoid Arthritis and Crohn's Disease patients treated with Cimzia aiming to evaluate the risk and incidence of Tuberculosis.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients who have been prescribed Cimzia Exclusion Criteria: * Any contra-indication according to the Russian Summary of Product Characteristic

What they're measuring

Incidence of Tuberculosis infection or reactivation during the study

Timeframe: From Baseline to Week 156 (Visit 7)

Trial details

NCT IDNCT01577264

SponsorUCB Pharma

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2015-10

View on ClinicalTrials.gov More Rheumatoid Arthritis trials